EFTA02572223.pdf

From: jeffrey E. <[email protected]> Sent: Friday, November 3, 2017 4:54 AM To: Masha Drokova Subject: Re: Gates said no one smarter On Fri, Nov 3, 2017 at 12:53 AM jeffrey E. <[email protected]> wrote: =/div> He is not an in=estor type . He is s partner at a firm but used to be at Microsoft. =ust use him for advice wrote: Th=nk you for the comprehensive feedback Steven. For me the main value is that the=system is an order of magnitude cheaper than existing technologies, premis=d on leveraging data to help users see what daily elements are affecting t=eir blood sugar, and predicting dangerous highs and lows before they happe= so they can take actions beforehand. To date, their beta app has lowered blood suga= averages in over 55% of users 2x better than the world's most prescri=ed diabetes drug, Metformin. Which means that with the help of the date di=betes would need to use less drugs. However I'd agree on complexity of regulatio=s and saturation on the market. I ru= Day One Ventures fund and based in San Francisco. I'd be happy to con=ect in person sometime to learn about about your experience and tell about=our investments and opportunities I see. On Nov 2, 2017, at 3:24 PM, Steven Sinofsk wrote:=br> Greetings Mash=, I apologize for the delay. I was at some =vents in in UK where I did not have connectivity. =/div> * In general the challenge with glucose measurement is the tinge= prick. Any device that relies on this will only be marginally better than=any other device, whether or not there is software or a slightly more conv=nient measuring device. This is a statement about the inconvenience of a p=ick (and long term challenges) but also the medical challenges on relying =n that point in time. * My sense is that going down the path of =n innovation, that still has a prick, but requires a level of FDA approval=is a difficult one to approach. * This is a very crowded space. =here are a lot of apps, a lot of measuring devices, a lot of mixtures of a=p and measuring devices. It is very difficult to avoid appearing as a comm=dity to consumers. * While I understand there is potential to se= innovation using novel approaches to analysis of data, it is not clear to=me how much better the approach can be for an individual with data. EFTA_R1_01741743 EFTA02572223  <=iv>' The real opportunity I might see is around measuring glucose or some =elated telemetry to assist in compliance that is outside the scope of a fi=ger prick and measuring glucose directly. It seems like we should have som= other data point upon which to apply machine learning. I hope this helps...any friend of JE is a friend of mine =br>On Nov 1, 2017, at 4:43 PM, Masha Drokova wrote: Thank you Jeffrey= Steve, great meeting you. Would appreciate your feedback=C240 On Nov 1, 2017, at 9:31 AM, jeffrey E. <[email protected]&g=; wrote: steve can you gi=e some guidance On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova wrote: =div> l'= looking to invest at the company doing AI-based glucose monitoring system=for people with diabetes. We made tech evaluation, talked to a few e=perts and more a question about the market and regulations. Likely no, 40=A0because it's complex area, but still thinking of them. <=div> <=div> May be someo=e in your network who knows this area and can advise on this kind of tech?=C240 Center Health Deck: <=pan>https://drive.google.com/file/d/0B5O93D3IJArEbXBsdll4e=Vob0U/view <https://drive.google.com/file/d/085O93O3IJArEbXBsdll4elVob0=> Our memo: https://docs.google.com/document/d/1M72V7VEI8CTnb4EtYWFH2sqSdcCm0PM6g1=IcwrIOtM chttps://docs.google=com/document/d/1M72V7VEI8CTnb4EtYWFH2sqSdcCm0PM6g1AlcwrIOtM> Center Health is building a= AI-based glucose monitoring system for the 1in 11 Americans who suf=er from diabetes, based on machine learning and their personalized Al,Q=A0Aria. Users subscribe to their disposable test strips, a $14B/yr US mark=t, which are delivered monthly, as Aria learns about their diabetes and pr=mpts behavioral changes to lower blood sugar. The system is an o=der of magnitude cheaper than existing technologies, premised on leveragin= data to help users see what daily elements are affecting their blood=sugar, and predicting dangerous highs and lows before they happen. </=ont> 2 EFTA_R1_01741744 EFTA02572224  Pros — Existing glucometers f=om big companies are very old-fashioned and outdated, those companies make=their revenue from overpriced strips — Direct compet=tors, such as iHealth and Dario have negative customer reviews=and minor — Uses FDA-approved circuits to get the approval i= an automated manner <=> Cons<f=pan> — Enormous pressure both from the industry players and compan=es such as Apple and Google that try to develop non-invasive glucose monit=ring that will wipe out test strip products — Hardw=re startup without a product to sell yet, finalizing the development — Young team <=blockquote> please note The information contained in this communication is confidential, may b= attorney-client privileged, may constitute inside information, and is =ntended only for the use of the addressee. It is the property of JEE=br>Unauthorized use, disclosure or copying of this communication or any=part thereof is strictly prohibited and may be unlawful. If you have re=eived this communication in error, please notify us immediately by r=turn e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication a=d all copies thereof, including all attachments. copyright -all rights =eserved Q=AO please note The information contained in this commu=ication is confidential, may be attorney-client privileged, may cons=itute inside information, and is intended only for the use of the addre=see. It is the property of JEE Unauthorized use, disclosure or copyi=g of this communication or any part thereof is strictly prohibited a=d may be unlawful. If you have received this communication in error, pl=ase notify us immediately by return e-mail or by e-mail to [email protected], a=d destroy this communication and all copies thereof, including all a=tachments. copyright -all rights reserved 3 EFTA_R1_01741745 EFTA02572225  4>=A0 please note The information contained in this=communication is confidential, may be attorney-client privileged, mayconstitute inside information, and is intended only for the use of the=addressee. It is the property of JEE Unauthorized use, disclosure or=copying of this communication or any part thereof is strictly prohibite= and may be unlawful. If you have received this communication in err=r, please notify us immediately by return e-mail or by e-mail to [email protected]<=a>, and destroy this communication and all copies thereof, including=all attachments. copyright -all rights reserved --001a113b48be66947f055d0ce3e7-- conversation-id 25269 date-last-viewed 0 date- received 1509684814 flags 8590195713 gmail-label-ids 7 6 remote-id 764742 4 EFTA_R1_01741746 EFTA02572226